NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy

The challenge to improve the clinical efficacy and enlarge the population that benefits from immune checkpoint inhibitors (ICIs) for non‐small‐cell lung cancer (NSCLC) is significant. Based on whole‐exosome sequencing analysis of biopsies from NSCLC patients before anti‐programmed cell death protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Xia, Liliang, Yao, Cheng‐cheng, Dong, Hui, Yang, Yi, Li, Chong, Ji, Wen‐xiang, Sun, Rui‐ming, Duan, Huang‐qi, Mengzhou, Wenli, Xia, Wei‐min, Wang, Shu‐jun, Ji, Ping, Li, Ziming, Jiao, Lei, Wang, Ying, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898729/
https://www.ncbi.nlm.nih.gov/pubmed/34927309
http://dx.doi.org/10.1111/cas.15243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898729/
https://www.ncbi.nlm.nih.gov/pubmed/34927309
http://dx.doi.org/10.1111/cas.15243

Ejemplares similares